ECSP24009853A - Compuestos tricíclicos como inhibidores de kras - Google Patents
Compuestos tricíclicos como inhibidores de krasInfo
- Publication number
- ECSP24009853A ECSP24009853A ECSENADI20249853A ECDI202409853A ECSP24009853A EC SP24009853 A ECSP24009853 A EC SP24009853A EC SENADI20249853 A ECSENADI20249853 A EC SENADI20249853A EC DI202409853 A ECDI202409853 A EC DI202409853A EC SP24009853 A ECSP24009853 A EC SP24009853A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- tricyclic compounds
- kras inhibitors
- kras
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940124785 KRAS inhibitor Drugs 0.000 title 1
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen compuestos de la Fórmula I, métodos de uso de los compuestos para inhibir la actividad de KRAS y composiciones farmacéuticas que comprenden tales compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de KRAS, tal como el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219274P | 2021-07-07 | 2021-07-07 | |
| US202163292774P | 2021-12-22 | 2021-12-22 | |
| US202263310811P | 2022-02-16 | 2022-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24009853A true ECSP24009853A (es) | 2024-03-01 |
Family
ID=84802055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20249853A ECSP24009853A (es) | 2021-07-07 | 2024-02-06 | Compuestos tricíclicos como inhibidores de kras |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230056631A1 (es) |
| EP (1) | EP4367117A1 (es) |
| JP (1) | JP2024527567A (es) |
| KR (1) | KR20240032915A (es) |
| AU (1) | AU2022306671A1 (es) |
| CA (1) | CA3224674A1 (es) |
| CL (1) | CL2024000043A1 (es) |
| CO (1) | CO2024001285A2 (es) |
| CR (1) | CR20240059A (es) |
| EC (1) | ECSP24009853A (es) |
| IL (1) | IL309642A (es) |
| MX (1) | MX2024000357A (es) |
| PE (1) | PE20241127A1 (es) |
| TW (1) | TW202317565A (es) |
| WO (1) | WO2023283213A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022192370A1 (en) | 2021-03-10 | 2022-09-15 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| IL312886A (en) * | 2021-11-22 | 2024-07-01 | Incyte Corp | Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor |
| IL314812A (en) | 2022-02-09 | 2024-10-01 | Quanta Therapeutics Inc | Kras modulators and uses thereof |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN119604501A (zh) | 2022-05-25 | 2025-03-11 | 光达治疗公司 | 基于嘧啶的调节剂及其用途 |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| TW202446371A (zh) * | 2023-04-18 | 2024-12-01 | 美商英塞特公司 | ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| ATE420879T1 (de) | 2001-09-19 | 2009-01-15 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
| EP1441737B1 (en) | 2001-10-30 | 2006-08-09 | Novartis AG | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| MEP46108A (en) | 2002-01-22 | 2011-02-10 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| CN103059138B (zh) | 2005-05-09 | 2015-10-28 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| ME02260B (me) | 2005-07-01 | 2016-02-29 | Medarex Inc | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EA201001030A1 (ru) | 2007-12-19 | 2011-02-28 | Амген Инк. | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| MY188826A (en) | 2008-12-09 | 2022-01-06 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| PT2632467T (pt) | 2010-10-25 | 2016-08-29 | G1 Therapeutics Inc | Inibidores cdk |
| AU2012230896B9 (en) | 2011-03-23 | 2015-06-18 | Amgen Inc. | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 |
| US10428064B2 (en) * | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| PE20181151A1 (es) | 2015-07-30 | 2018-07-17 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| IL263825B (en) | 2016-06-20 | 2022-08-01 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
| MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
| KR102641030B1 (ko) | 2016-12-22 | 2024-02-29 | 인사이트 코포레이션 | Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체 |
| SG11202009440WA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| US10618916B2 (en) | 2018-05-11 | 2020-04-14 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JP7667160B2 (ja) | 2020-01-10 | 2025-04-22 | インサイト コーポレーション | Ｋｒａｓの阻害剤としての三環式化合物 |
| IL312886A (en) * | 2021-11-22 | 2024-07-01 | Incyte Corp | Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor |
-
2022
- 2022-07-06 MX MX2024000357A patent/MX2024000357A/es unknown
- 2022-07-06 EP EP22755335.1A patent/EP4367117A1/en active Pending
- 2022-07-06 JP JP2024500207A patent/JP2024527567A/ja active Pending
- 2022-07-06 CR CR20240059A patent/CR20240059A/es unknown
- 2022-07-06 KR KR1020247003914A patent/KR20240032915A/ko active Pending
- 2022-07-06 US US17/810,915 patent/US20230056631A1/en active Pending
- 2022-07-06 TW TW111125417A patent/TW202317565A/zh unknown
- 2022-07-06 IL IL309642A patent/IL309642A/en unknown
- 2022-07-06 WO PCT/US2022/036172 patent/WO2023283213A1/en active IP Right Grant
- 2022-07-06 PE PE2024000044A patent/PE20241127A1/es unknown
- 2022-07-06 AU AU2022306671A patent/AU2022306671A1/en active Pending
- 2022-07-06 CA CA3224674A patent/CA3224674A1/en active Pending
-
2024
- 2024-01-05 CL CL2024000043A patent/CL2024000043A1/es unknown
- 2024-02-06 CO CONC2024/0001285A patent/CO2024001285A2/es unknown
- 2024-02-06 EC ECSENADI20249853A patent/ECSP24009853A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024527567A (ja) | 2024-07-25 |
| TW202317565A (zh) | 2023-05-01 |
| CL2024000043A1 (es) | 2024-07-19 |
| IL309642A (en) | 2024-02-01 |
| EP4367117A1 (en) | 2024-05-15 |
| KR20240032915A (ko) | 2024-03-12 |
| CO2024001285A2 (es) | 2024-03-07 |
| WO2023283213A1 (en) | 2023-01-12 |
| CA3224674A1 (en) | 2023-01-12 |
| PE20241127A1 (es) | 2024-05-24 |
| MX2024000357A (es) | 2024-02-12 |
| CR20240059A (es) | 2024-03-21 |
| AU2022306671A1 (en) | 2024-01-25 |
| US20230056631A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP24035717A (es) | Compuestos de quinolina como inhibidores de kras | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CL2022002985A1 (es) | Inhibidores de pi3k y métodos de uso de los mismos | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| CO2023008475A2 (es) | Inhibidores de enzimas | |
| UY39865A (es) | Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| ECSP24007534A (es) | Inhibidores de transglutaminasas | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| MX2024008413A (es) | Compuestos macrocíclicos y uso como inhibidores de cinasas. | |
| AR117459A1 (es) | Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos | |
| MX2023007297A (es) | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. | |
| CO2024017767A2 (es) | Sales de inhibidores de sos1 | |
| EA202191738A1 (ru) | Соединения имидазопиридазина и имидазопиридина и их применение |